HRTX EBITDA Growth
Heron Therapeutics Inc · EBITDA Growth
HRTX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-507.03%period ending
HRTX TTM EBITDA YoY % (-43.90% → -507.03%)
Year-over-year change
High-resolution chart · PNG
HRTX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -507.0318% | |
| -5,491.939% | |
| -162.5316% | |
| 82.8792% | |
| 117.4691% | |
| 100.6329% | |
| 94.9985% | |
| 83.9976% | |
| 71.6597% | |
| 52.7191% | |
| 44.3568% | |
| 43.0026% | |
| 37.8499% | |
| 32.8065% | |
| 14.7738% | |
| 3.5562% | |
| 1.485% | |
| -2.9298% | |
| 2.7106% | |
| -2.3113% | |
| -17.7561% | |
| -17.2801% | |
| -10.5833% | |
| -11.989% | |
| 3.6057% | |
| -0.9793% | |
| -15.2174% | |
| 0.03% | |
| -3.8936% | |
| 4.2864% | |
| 9.5178% | |
| -8.7013% | |
| -4.5855% | |
| -5.6078% | |
| -13.9609% | |
| -15.4253% | |
| -43.0078% | |
| -70.3452% | |
| -76.6233% | |
| -79.7493% | |
| -56.8452% | |
| -39.6177% | |
| -28.0326% | |
| -25.1126% | |
| -31.9916% | |
| -32.8275% | |
| -38.3922% | |
| -39.7133% | |
| -46.6939% | |
| -85.6098% | |
| -129.0048% | |
| -155.9377% | |
| -146.7893% | |
| -120.4409% | |
| -117.1644% | |
| -125.3209% | |
| -185.0954% | |
| -75.4468% | |
| -12.115% | |
| 15.403% | |
| 37.1217% | |
| 16.7685% | |
| 1.8106% | |
| 13.4816% | |
| 42.4401% | |
| 48.1102% | |
| 57.0771% | |
| 57.0826% | |
| 36.2086% | |
| 21.1068% | |
| 0.1474% | |
| -28.328% | |
| -32.541% | |
| -17.7701% | |
| -24.0975% | |
| -38.2334% | |
| -49.0011% | |
| -84.3201% | |
| -133.9753% | |
| -93.523% | |
| -66.8224% | |
| -42.7316% | |
| 12.3856% | |
| 4.0107% | |
| -6.9827% | |
| -12.1432% | |
| -47.4069% | |
| -64.0272% | |
| -38.2891% | |
| -37.3333% | |
| -38.6297% | |
| 17.7332% | |
| 18.5456% | |
| 23.6438% | |
| 33.8058% | |
| 6.7924% | |
| -19.9453% | |
| -32.3612% | |
| -53.2465% | |
| -434.5902% |